JP2011527335A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011527335A5 JP2011527335A5 JP2011517249A JP2011517249A JP2011527335A5 JP 2011527335 A5 JP2011527335 A5 JP 2011527335A5 JP 2011517249 A JP2011517249 A JP 2011517249A JP 2011517249 A JP2011517249 A JP 2011517249A JP 2011527335 A5 JP2011527335 A5 JP 2011527335A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- alkyl
- compound
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003839 salts Chemical class 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- 125000006164 6-membered heteroaryl group Chemical group 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0812649.2 | 2008-07-10 | ||
| GBGB0812649.2A GB0812649D0 (en) | 2008-07-10 | 2008-07-10 | Compounds |
| PCT/GB2009/050831 WO2010004348A1 (en) | 2008-07-10 | 2009-07-10 | Heterocyclic gpcr agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011527335A JP2011527335A (ja) | 2011-10-27 |
| JP2011527335A5 true JP2011527335A5 (enExample) | 2012-08-16 |
Family
ID=39722074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011517249A Withdrawn JP2011527335A (ja) | 2008-07-10 | 2009-07-10 | ヘテロ環式ｇｐｃｒ作動薬 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110178054A1 (enExample) |
| EP (1) | EP2321305A1 (enExample) |
| JP (1) | JP2011527335A (enExample) |
| CN (1) | CN102089298A (enExample) |
| GB (1) | GB0812649D0 (enExample) |
| WO (1) | WO2010004348A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010114907A1 (en) | 2009-03-31 | 2010-10-07 | Vanderbilt University | Sulfonyl-azetidin-3-yl-methylamine amide analogs as glyt1 inhibitors, methods for making same, and use of same in treating psychiatric disorders |
| US8481731B2 (en) | 2009-06-24 | 2013-07-09 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical composition and methods relating thereto |
| US8293729B2 (en) | 2009-06-24 | 2012-10-23 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical composition and methods relating thereto |
| US20130109703A1 (en) | 2010-03-18 | 2013-05-02 | Boehringer Ingelheim International Gmbh | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions |
| TW201209054A (en) | 2010-05-28 | 2012-03-01 | Prosidion Ltd | Novel compounds |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| GB201114389D0 (en) | 2011-08-22 | 2011-10-05 | Prosidion Ltd | Novel compounds |
| AR083904A1 (es) | 2010-11-18 | 2013-04-10 | Prosidion Ltd | Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos |
| JP5935154B2 (ja) * | 2011-03-14 | 2016-06-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｇｐｒ１１９モジュレーターとしてのｎ−シクロプロピル−ｎ−ピペリジニルベンズアミド |
| US8957062B2 (en) | 2011-04-08 | 2015-02-17 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
| WO2012168315A1 (en) | 2011-06-09 | 2012-12-13 | Boehringer Ingelheim International Gmbh | Substituted piperidines as gpr119 modulators for the treatment of metabolic disorders |
| WO2012170867A1 (en) | 2011-06-09 | 2012-12-13 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of gpr-119 |
| WO2012173917A1 (en) | 2011-06-16 | 2012-12-20 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760855B1 (en) | 2011-09-30 | 2017-03-15 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds as well as their use in treating type-2 diabetes |
| US9018200B2 (en) | 2011-10-24 | 2015-04-28 | Merck Sharp & Dohme Corp. | Substituted piperidinyl compounds useful as GPR119 agonists |
| US9018224B2 (en) | 2011-11-15 | 2015-04-28 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds useful as GPR119 agonists |
| GB2498976A (en) * | 2012-02-01 | 2013-08-07 | Prosidion Ltd | GPR119 agonists useful in the treatment of type II diabetes |
| US8809259B2 (en) | 2012-03-26 | 2014-08-19 | Pronutria, Inc. | Charged nutritive proteins and methods |
| EP2872127A1 (en) | 2012-07-11 | 2015-05-20 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| US20160354436A1 (en) | 2013-09-25 | 2016-12-08 | Pronutria Biosciences, Inc. | Compositions and Formulations for Increasing Renal Function and Treatment and Prevention of Renal Diseases, and Methods of Production and Use Thereof |
| WO2018068295A1 (en) * | 2016-10-14 | 2018-04-19 | Merck Sharp & Dohme Corp. | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE |
| EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6100042A (en) * | 1993-03-31 | 2000-08-08 | Cadus Pharmaceutical Corporation | Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor |
| CA2262569A1 (en) * | 1996-08-09 | 1998-02-19 | Norihito Ohi | Benzopiperidine derivatives |
| US5834261A (en) * | 1997-05-27 | 1998-11-10 | Biocatalytics, Inc. | Method for the production of chiral vicinal aminoalcohols |
| US6221660B1 (en) * | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
| BRPI0613505A2 (pt) * | 2005-06-30 | 2011-01-11 | Prosidion Ltd | agonistas de gpcr |
| WO2008008895A1 (en) * | 2006-07-13 | 2008-01-17 | Smithkline Beecham Corporation | Gpr119 agonists for the treatment of diabetes and related disorders |
| CL2008000018A1 (es) * | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
| JP2010514828A (ja) * | 2007-01-04 | 2010-05-06 | プロシディオン・リミテッド | ピペリジンｇｐｃｒアゴニスト |
| BRPI0806312A2 (pt) * | 2007-01-04 | 2011-09-06 | Prosidion Ltd | agonistas cgpr piperidina |
| CL2008000017A1 (es) * | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
| GB0700122D0 (en) * | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
-
2008
- 2008-07-10 GB GBGB0812649.2A patent/GB0812649D0/en not_active Ceased
-
2009
- 2009-07-10 EP EP09785309A patent/EP2321305A1/en not_active Withdrawn
- 2009-07-10 WO PCT/GB2009/050831 patent/WO2010004348A1/en not_active Ceased
- 2009-07-10 US US13/003,573 patent/US20110178054A1/en not_active Abandoned
- 2009-07-10 JP JP2011517249A patent/JP2011527335A/ja not_active Withdrawn
- 2009-07-10 CN CN2009801269686A patent/CN102089298A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011527335A5 (enExample) | ||
| JP2011527334A5 (enExample) | ||
| JP2011500658A5 (enExample) | ||
| JP2008525416A5 (enExample) | ||
| JP2011527332A5 (enExample) | ||
| JP2010514832A5 (enExample) | ||
| RU2485131C2 (ru) | Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой и содержащие их противогрибковые средства | |
| JP2009532453A5 (enExample) | ||
| JP2006143751A5 (enExample) | ||
| CA2529464A1 (en) | Propionamide derivatives useful as androgen receptor modulators | |
| JP2010514831A5 (enExample) | ||
| JP2009533410A5 (enExample) | ||
| JP2019500387A5 (enExample) | ||
| JP2011527333A5 (enExample) | ||
| JP2011527331A5 (enExample) | ||
| JP2013510123A5 (enExample) | ||
| RU2018127728A (ru) | Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич | |
| JP2010525056A5 (enExample) | ||
| JP2008534453A5 (enExample) | ||
| JP2009504763A5 (enExample) | ||
| JP2014505660A5 (enExample) | ||
| JP2010511626A5 (enExample) | ||
| JP2008540554A5 (enExample) | ||
| JP2013508279A5 (enExample) | ||
| JP2014505107A5 (enExample) |